Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Nab-PP + rh-Endostatin in Advanced Sq-NSCLC
NCT06747169Phase 2Not yet recruiting
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of sintilimab, endostar in squamous cell carcinoma of the lung (SCCL). Planned start Dec 2024; status: not yet recruiting.
02
Drugs
sintilimabendostar
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT06747169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06747169.